Blumberger DM

Department of Psychiatry, Temerty Faculty of Medicine, https://ror.org/03dbr7087University of Toronto, Toronto, Ontario, Canada.

12 papers · ORCID

ArticlePsilocybin

Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study.

Ledwos N, Baer J, Husain MI +11

Europe PMC2025
ArticlePsilocybin

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.

Konstantinou GN, Rosenblat J, Hales S +2

Europe PMC2026
ArticleKetamine

Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.

Kaster TS, Dai Y, Vila-Rodriguez F +4

Europe PMC2025
ArticlePsilocybin

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.

Wong S, Jones BDM, Thiyagarajah MT +10

Europe PMC2025
ArticlePsilocybin

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.

Wong S, Meckling G, Fabiano N +11

Europe PMC2025
ArticlePsilocybin

Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.

Kittur ME, Burgos M LA, Jones BDM +4

Europe PMC2025
ArticlePsychedelics

A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.

Wen A, Singhal N, Jones BDM +6

Europe PMC2024
ArticlePsilocybin

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.

Wong S, Yu AY, Fabiano N +7

Europe PMC2024
ArticlePsilocybin

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.

Husain MI, Blumberger DM, Castle DJ +8

Europe PMC2023
ArticlePsilocybin

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?

Husain MI, Ledwos N, Fellows E +5

Europe PMC2022
ArticlePsilocybin

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.

Ledwos N, Rosenblat JD, Blumberger DM +4

Europe PMC2022
ArticlePsilocybin

Management of Treatment-Resistant Depression: Challenges and Strategies.

Voineskos D, Daskalakis ZJ, Blumberger DM

Europe PMC2020